Nisa Investment Advisors LLC Has $6.68 Million Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Nisa Investment Advisors LLC raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.2% in the fourth quarter, HoldingsChannel reports. The fund owned 63,099 shares of the medical equipment provider’s stock after acquiring an additional 729 shares during the period. Nisa Investment Advisors LLC’s holdings in Zimmer Biomet were worth $6,680,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in ZBH. Equity Investment Corp acquired a new position in Zimmer Biomet in the 3rd quarter valued at $70,104,000. Hotchkis & Wiley Capital Management LLC boosted its position in shares of Zimmer Biomet by 49.1% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 1,752,298 shares of the medical equipment provider’s stock valued at $189,161,000 after acquiring an additional 577,320 shares during the period. Van ECK Associates Corp grew its stake in shares of Zimmer Biomet by 12.4% in the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider’s stock valued at $391,239,000 after acquiring an additional 411,163 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new position in Zimmer Biomet during the third quarter worth about $41,588,000. Finally, D. E. Shaw & Co. Inc. boosted its holdings in Zimmer Biomet by 329.2% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 490,138 shares of the medical equipment provider’s stock valued at $53,195,000 after purchasing an additional 375,929 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the stock. Truist Financial raised their target price on shares of Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a report on Wednesday, December 18th. Barclays dropped their price objective on Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating for the company in a report on Thursday, December 12th. Oppenheimer reduced their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a report on Tuesday, October 15th. Royal Bank of Canada boosted their price target on Zimmer Biomet from $120.00 to $125.00 and gave the company an “outperform” rating in a research note on Monday, November 4th. Finally, Evercore ISI reduced their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a research note on Tuesday, October 1st. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Zimmer Biomet presently has an average rating of “Hold” and a consensus target price of $124.11.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $110.78 on Friday. The stock has a 50-day moving average price of $107.89 and a two-hundred day moving average price of $108.09. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The company has a market capitalization of $22.05 billion, a PE ratio of 21.06, a P/E/G ratio of 1.88 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same period last year, the company earned $1.65 EPS. The firm’s revenue was up 4.1% compared to the same quarter last year. Analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio is currently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.